Hideki Yoshioka

Oct 20, 2024 | nature.com | Hiromi Sato |Hideki Yoshioka |Ryota Jin

AbstractThis study was aimed to evaluate whether the dose–response relationship of the sodium glucose co-transporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)—canagliflozin, dapagliflozin, empagliflozin, ipragliflozin, luseogliflozin, and tofogliflozin—can be explained in a unified manner based on their ability to promote urinary glucose excretion (UGE).

Feb 19, 2024 | ascpt.onlinelibrary.wiley.com | Hideki Yoshioka |Hiromi Sato |Ryota Jin |Akihiro Hisaka

WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? Progression of Parkinson's disease (PD) was most often assessed by linear regression of specific biomarker changes during a limited period of observation. The effect of patient characteristics, such as genetic mutations, on disease progression has not been fully elucidated because an integrated analysis of nonlinear changes in multiple biomarkers over longer periods than observation has not been realized. WHAT QUESTION DID THIS STUDY ADDRESS?